Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-06-17

Clinical Trial Update: A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of CD22-CAR T cell immunotherapy for CD22-positive leukemia and lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CD22-CAR T cell immunotherapy

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING